Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3912 + fulvestrant ± TQB3616 in HR-positive, HER2-negative advanced breast cancer
CTR20244912Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tqb3912 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2024; status: terminated.
02
Drugs
tqb3912
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244912.